Multi-drug resistance as a problem challenging breast cancer chemotherapy

Samar S. Azab, Ebtehal El-Demerdash, Ayman Al-Hendy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Success in breast cancer chemotherapy is challenged by the development of tumors having a multi-drug resistance (MDR) phenotype. It is one of the major causes of failure to cancer chemotherapy. MDR is a multi-factorial problem, where several mechanisms are acting in concert with each other for the development of MDR phenomenon. Though many of the underlying mechanisms are still not clearly identified, several potential molecular targets and pathways of activation have been suggested. The advances in this field provide an emerging picture of how MDR arises and how it could be therapeutically targeted. In this chapter, we review recent experimental and clinical evidence of the different molecular basis of MDR. Also, we review the relevance of using different MDR inhibitors (benefits and problems).

Original languageEnglish (US)
Title of host publicationAggressive Breast Cancer
PublisherNova Science Publishers, Inc.
Pages53-100
Number of pages48
ISBN (Electronic)9781617618642
ISBN (Print)9781608768813
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Breast Neoplasms
Drug Therapy
Neoplasms
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Azab, S. S., El-Demerdash, E., & Al-Hendy, A. (2010). Multi-drug resistance as a problem challenging breast cancer chemotherapy. In Aggressive Breast Cancer (pp. 53-100). Nova Science Publishers, Inc..

Multi-drug resistance as a problem challenging breast cancer chemotherapy. / Azab, Samar S.; El-Demerdash, Ebtehal; Al-Hendy, Ayman.

Aggressive Breast Cancer. Nova Science Publishers, Inc., 2010. p. 53-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Azab, SS, El-Demerdash, E & Al-Hendy, A 2010, Multi-drug resistance as a problem challenging breast cancer chemotherapy. in Aggressive Breast Cancer. Nova Science Publishers, Inc., pp. 53-100.
Azab SS, El-Demerdash E, Al-Hendy A. Multi-drug resistance as a problem challenging breast cancer chemotherapy. In Aggressive Breast Cancer. Nova Science Publishers, Inc. 2010. p. 53-100
Azab, Samar S. ; El-Demerdash, Ebtehal ; Al-Hendy, Ayman. / Multi-drug resistance as a problem challenging breast cancer chemotherapy. Aggressive Breast Cancer. Nova Science Publishers, Inc., 2010. pp. 53-100
@inbook{c706b1dac921469f874cc99033dd6964,
title = "Multi-drug resistance as a problem challenging breast cancer chemotherapy",
abstract = "Success in breast cancer chemotherapy is challenged by the development of tumors having a multi-drug resistance (MDR) phenotype. It is one of the major causes of failure to cancer chemotherapy. MDR is a multi-factorial problem, where several mechanisms are acting in concert with each other for the development of MDR phenomenon. Though many of the underlying mechanisms are still not clearly identified, several potential molecular targets and pathways of activation have been suggested. The advances in this field provide an emerging picture of how MDR arises and how it could be therapeutically targeted. In this chapter, we review recent experimental and clinical evidence of the different molecular basis of MDR. Also, we review the relevance of using different MDR inhibitors (benefits and problems).",
author = "Azab, {Samar S.} and Ebtehal El-Demerdash and Ayman Al-Hendy",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781608768813",
pages = "53--100",
booktitle = "Aggressive Breast Cancer",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Multi-drug resistance as a problem challenging breast cancer chemotherapy

AU - Azab, Samar S.

AU - El-Demerdash, Ebtehal

AU - Al-Hendy, Ayman

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Success in breast cancer chemotherapy is challenged by the development of tumors having a multi-drug resistance (MDR) phenotype. It is one of the major causes of failure to cancer chemotherapy. MDR is a multi-factorial problem, where several mechanisms are acting in concert with each other for the development of MDR phenomenon. Though many of the underlying mechanisms are still not clearly identified, several potential molecular targets and pathways of activation have been suggested. The advances in this field provide an emerging picture of how MDR arises and how it could be therapeutically targeted. In this chapter, we review recent experimental and clinical evidence of the different molecular basis of MDR. Also, we review the relevance of using different MDR inhibitors (benefits and problems).

AB - Success in breast cancer chemotherapy is challenged by the development of tumors having a multi-drug resistance (MDR) phenotype. It is one of the major causes of failure to cancer chemotherapy. MDR is a multi-factorial problem, where several mechanisms are acting in concert with each other for the development of MDR phenomenon. Though many of the underlying mechanisms are still not clearly identified, several potential molecular targets and pathways of activation have been suggested. The advances in this field provide an emerging picture of how MDR arises and how it could be therapeutically targeted. In this chapter, we review recent experimental and clinical evidence of the different molecular basis of MDR. Also, we review the relevance of using different MDR inhibitors (benefits and problems).

UR - http://www.scopus.com/inward/record.url?scp=85029939942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029939942&partnerID=8YFLogxK

M3 - Chapter

SN - 9781608768813

SP - 53

EP - 100

BT - Aggressive Breast Cancer

PB - Nova Science Publishers, Inc.

ER -